ARA-290, also called cibinetide, is an investigational peptide studied for small-fiber neuropathy. Some early human trials reported changes in nerve-fiber measurements or symptoms, but the evidence does not establish a general treatment that reliably repairs nerves or eliminates pain. A key distinction is whether a study measured nerve structure, a symptom questionnaire or meaningful improvement in everyday life. [1][2]
If you’re living with burning, tingling or persistent nerve pain, the question is understandably “Will this help me?” A change in a nerve measurement doesn’t necessarily answer it.
Related reference: The ARA-290 16 mg vial page covers concentration calculations. It does not establish suitability for a particular neuropathy or replace a clinician’s assessment.
What is ARA-290 peptide?
ARA-290 was designed from erythropoietin (EPO) to investigate tissue-protective signaling without EPO’s red-blood-cell-producing action. That’s what “nonerythropoietic” means. Researchers study its interaction with the innate repair receptor, a signaling system involved in responses to tissue injury. [3]
This is a rationale for developing a treatment, not proof that the compound repairs every type of injury. Neuropathy is a broad category with many causes, and results in one group cannot simply be applied to all nerve pain.
What have the human trials found?
| Study | Main finding and limitation |
|---|---|
| 2012 sarcoidosis pilot | Twenty-two participants. A neuropathy symptom score favored ARA-290, but a pain-intensity measure improved similarly in both treatment and placebo groups. [1] |
| 2017 sarcoidosis trial | Sixty-four participants. One tested dose improved the primary corneal nerve-fiber endpoint. A reported pain comparison did not reach conventional statistical significance. [2] |
| Type 2 diabetes study | A small phase 2 trial reported changes in metabolic measures and neuropathic symptoms. It called for further clinical evaluation, not routine adoption. [3] |
Sarcoidosis-associated small-fiber neuropathy
The 2012 randomized, double-blind pilot compared ARA-290 with placebo for four weeks. The small-fiber neuropathy screening score improved more with treatment, while Brief Pain Inventory scores improved in both groups without a between-group advantage. Different questionnaires were answering different questions. [1]
In the 2017 phase 2b trial, investigators tested three doses against placebo for 28 days. The middle-dose group improved the primary corneal nerve-fiber area endpoint; the other dose groups did not show the same statistically significant result. The pain comparison highlighted in participants with moderate-to-severe pain had a P value of 0.157. It was not a statistically confirmed pain benefit. [2]
Type 2 diabetes and neuropathic symptoms
Another study used 28 days of treatment followed by a month of observation. Researchers reported improvements in HbA1c and a neuropathic symptom questionnaire. A corneal nerve-fiber finding came from participants whose baseline measurements were substantially below normal. That is not the same as showing uniform nerve regrowth in every participant. [3]
These are useful signals for further work. They are still short studies with limited populations. Larger, independent trials with patient-centered outcomes would give a clearer answer about lasting benefit.
Does ARA-290 regenerate nerves?
The strongest phrasing supported by these studies is that researchers observed changes in selected small-nerve-fiber measurements. The 2017 study used corneal microscopy and skin measures as indicators of possible disease modification. [2]
That is more specific than saying “it regenerates nerves.” It does not show that a severed nerve reconnects, that every cause of neuropathy responds, or that improved microscopy always produces less pain. A surrogate endpoint is a measurement used as a stand-in for an outcome we ultimately care about.
How long does it take to work?
Four weeks is a common assessment period in the studies above, not a guaranteed onset. The trials do not establish a dependable day when someone should expect relief, or how long any improvement will persist outside the studied setting. [1][3]
Symptoms also fluctuate. Tracking pain, sleep and function can help a clinical assessment, but a personal improvement cannot by itself identify which treatment caused it.
Side effects and safety: what remains unknown?
The 2012 pilot and the diabetes study did not identify major treatment-related safety signals during their short observation periods. Small studies cannot rule out uncommon adverse effects, delayed problems or risks with a different preparation. [1][3]
ARA-290’s design aims to avoid EPO’s blood-cell effects. That should not be expanded into a claim that it has no cardiovascular, immune or other risks. Likewise, a product sold under the same name is not automatically equivalent to the formulation used in a clinical trial.
Does orphan-drug designation mean it is approved?
No. EMA granted cibinetide an orphan designation for sarcoidosis, a development status intended for medicines targeting rare conditions. EMA explicitly distinguishes that designation from marketing authorization: quality, safety and efficacy still need to be demonstrated. [4]
The evidence discussed here concerns an investigational treatment. A database identifier, orphan designation or research-product listing should not be presented as proof of an approved neuropathy medicine.
Can ARA-290 be combined with BPC-157?
The cited trials do not establish the benefits or safety of that combination. Separate research on two compounds is not evidence that combining them is better, safer or necessary. It also makes it harder to identify the cause of a benefit or adverse reaction.
Where is ARA-290 injected, and is there a standard dose?
Studies have used different routes, including intravenous and subcutaneous administration. Their study regimens should not be treated as a universal self-injection protocol. The clinical question, formulation and monitoring are part of the intervention, not optional extras. [1][3]
What should someone with nerve pain do first?
Get the cause and type of neuropathy assessed. NINDS describes treatment as depending on the underlying condition, affected nerves and symptoms. Correcting a cause, protecting numb areas from injury and choosing appropriate pain management may all matter. [5]
Bottom line: ARA-290 has early human research worth understanding, particularly in sarcoidosis-associated small-fiber neuropathy. Its nerve-measurement findings are not a blanket promise of pain relief. Discuss persistent or worsening symptoms with a qualified clinician rather than replacing established care with an unvalidated peptide combination.
Related ARA-290 dosage protocols
Continue with the vial-strength-specific research protocol that matches the material being evaluated. Each page keeps its own concentration, reconstitution, and syringe-unit calculations.
Practical measurement and handling guides
References
- Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy. Molecular Medicine. 2012.
- Culver DA, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Investigative Ophthalmology & Visual Science. 2017.
- Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine. Published online 2014; indexed 2015.
- European Medicines Agency. EU/3/13/1191: cibinetide orphan designation for sarcoidosis.
- NINDS. Peripheral neuropathy.